Sun Pharma share price in focus on Monday after Trump's tariff announcement

The Indian pharmaceutical sector, heavily reliant on exports to the US, faces increased regulatory and pricing pressure from new US trade policies. This could impact revenue and profitability for companies with significant US market share.

Maintain a bearish bias on Indian pharma stocks with high US exposure; look for short opportunities on any relief rallies, with strict stop-losses.

For Indian markets, this story mainly matters for SUNPHARMA and the Pharmaceuticals pocket. The current signal is bearish, so traders should look for follow-through in price, volume, and sector breadth instead of reacting to the headline alone.

Watch whether the next market session confirms the setup described here: Directly mentioned as facing potential tariffs on innovative products due to new US policy. Also track volume confirmation, sector participation, and whether the move holds beyond the first reaction.

• •Sun Pharma shares will be in focus on April 6 due to President Trump's new executive order.
• •The executive order imposes 100% tariffs on imported branded drugs unless companies lower prices or produce domestically.
• •Jefferies reports that Sun Pharma may only face up to 15% tariffs on its innovative products.
• •Risk flag: Uncertainty regarding the full scope and implementation of the US tariff policy.
• •Risk flag: Potential for companies to mitigate impact by localizing production or adjusting pricing.